Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

In this article, we are going to take a look at where Gossamer Bio, Inc. (NASDAQ:GOSS) stands against other best penny stocks to buy according to the media. On December 24, Global Advisors ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated price target remains the same with $10.00. Patrick Trucchio ...

Overview: Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension in the ...

SAN DIEGO, January 28, 2025--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

SAN DIEGO, CA – Gossamer Bio, Inc. (GOSS), a pharmaceutical company based in San Diego, announced today that it has regained compliance with the Nasdaq's minimum bid price requirement ...

I love when dramatic fluttery eyelashes make an appearance on the runway, but the fall 2025 Thom Browne show took eye makeup ...

The Gossamer-1 project is concerned with the development and establishment of a space-qualified technology for the deployment of ultra-light, large foil structures in space. The core technologies are ...

总部位于圣地亚哥的制药公司Gossamer Bio, Inc. (GOSS)今日宣布，其已重新符合纳斯达克最低竞价要求，解决了其在纳斯达克全球精选市场持续上市的问题。该公司股票目前交易价格为$1.42，过去六个月涨幅达47.86%。